Comment on proposed draft Local Coverage Determinations (LCDs) on skin substitutes

London, UK, 26 April – Convatec, a leading medical products and technologies company, notes the start of a forty-five day public consultation period with respect to the newly proposed draft Local Coverage Determinations (LCDs) “Skin Substitute Grafts / Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers”.

As we have previously noted, the reimbursement environment in this segment is dynamic. Last year, a similar process resulted in no change in coverage. This is the beginning of a new LCD process and there is no certainty as to the timing or outcomes that may or may not result.

Convatec will actively engage with all relevant parties over the course of the consultation period. We seek an outcome that preserves choice for clinicians treating chronic wounds and is in the best interest of patients.

We are confident in the clinical efficacy of our InnovaMatrix® platform and continue to build our clinical evidence portfolio. Clinicians and patients have experienced first-hand the positive impact InnovaMatrix® products have on chronic wounds.

Contact
Investor Relations: IR@convatec.com
Media: MediaRelations@convatec.com

About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in advanced wound care, ostomy care, continence care and infusion care. With around 10,000 colleagues, we provide our products and services in almost 100 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Convatec’s revenues in 2023 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more about Convatec, please visit http://www.convatecgroup.com

Press Release

See all

16-Dec-24

Corporate

Continence Care

Convatec unveils new resources to support intermittent catheter users to live life confidently

me+ programme offers free practical tools for intermittent catheter users including emotional wellbeing support

14-Nov-24

Corporate

Convatec responds to Local Coverage Determinations (LCDs) on skin substitutes

12-Nov-24

Corporate

Financial Performance

Trading update for the ten months ended 31 October 2024

Convatec upgrades FY24 guidance; on-track for double-digit EPS growth in 2024 and 2025

21-Oct-24

Corporate

Infusion Care

Convatec collaborates with AbbVie for VYALEV™ therapy for the treatment of advanced Parkinson’s disease in the United States

Convatec’s Neria™ Guard will be used to deliver AbbVie’s VYALEV™ therapy (foscarbidopa and foslevodopa) in the United States, following FDA approval

10-Oct-24

Corporate

Advanced Wound Care

Convatec update on InnovaMatrix® AC clinical data – second randomised controlled trial authorised

Convatec continues to advance clinical evidence for InnovaMatrix® AC

20-Sep-24

Corporate

Advanced Wound Care

Convatec update on InnovaMatrix® AC clinical data

InnovaMatrix® AC is a pioneering technology in the treatment of wounds

21-Aug-24

Corporate

Continence Care

Comment on the announcement of CMS changes to catheter codes

01-Aug-24

Continence Care

Convatec me+ Companion™ App offers support for millions of intermittent catheter users

New free app offers users a practical tool to ensure their cathing journey starts smoothly

30-Jul-24

Corporate

Financial Performance

Interim Results for the six months ended 30 June 2024

Strong broad-based revenue growth and further strategic progress

26-Jul-24

Continence Care

Convatec’s pioneering catheter for women continues to scale up in Europe

The new compact offering blends gentle, protective cathing with everyday discretion and ease of use.

16-May-24

Corporate

Financial Performance

a person holding a person's hand while he is holding a coat

AGM trading update for the four months ended 30 April 2024

Revenue continued to build, further strategic progress, on track to deliver financial guidance

01-May-24

Advanced Wound Care

Convatec unveils significant advanced wound care clinical study results

New research demonstrates superiority of AQUACEL® Ag+ Extra™ dressing in the management of venous leg ulcers

26-Apr-24

Corporate

Comment on proposed draft Local Coverage Determinations (LCDs) on skin substitutes

06-Mar-24

Corporate

Financial Performance

Annual Results for the twelve months ended 31 December 2023

29-Feb-24

Ostomy Care

Convatec launches new Esteem Body™ with Leak Defense™

11-Jan-24

Infusion Care

Convatec expands support for people living with advanced Parkinson´s disease